| 000 | 01706ngm a2200361 a 4500 | ||
|---|---|---|---|
| 001 | HST3380_1_2 | ||
| 003 | UkLoHST | ||
| 006 | m c | ||
| 007 | cr|cna|||a|||| | ||
| 007 | vz|czazum | ||
| 008 | 130417s2013 enk|||||||||||s|||v|eng d | ||
| 028 | 5 | 0 |
_a3380 _bHenry Stewart Talks |
| 035 | _a(UkLoHST)2503 | ||
| 040 |
_aUkLoHST _beng _cUkLoHST |
||
| 100 | 1 |
_aNunn, Andrew, _u(MRC Clinical Trials Unit, UK) _4spk |
|
| 245 | 1 | 4 |
_aThe development of current treatments for tuberculosis _h[electronic resource] / _cAndrew Nunn. |
| 260 |
_aLondon : _bHenry Stewart Talks, _c2013. |
||
| 300 |
_a1 online resource (1 streaming video file (28 min.) : _bcolor, sound). |
||
| 490 | 1 |
_aTuberculosis, _x2056-452X |
|
| 500 | _aAnimated audio-visual presentation with synchronized narration. | ||
| 500 | _aTitle from title frames. | ||
| 505 | 0 | _aContents: Early trials demonstrated the need for giving more than one drug to avoid the problems of acquired drug resistance -- Short course chemotherapy highly effective provided rifampicin given throughout -- HIV coinfection has presented new challenges to effective treatment -- New methods needed to identify potential regimen candidates for phase III. | |
| 506 | _aAccess restricted to subscribers. | ||
| 538 | _aMode of access: World Wide Web. | ||
| 650 | 0 | _aAntitubercular agents | |
| 650 | 0 |
_aTuberculosis _xChemotherapy. |
|
| 650 | 0 |
_aTuberculosis _xTreatment. |
|
| 650 | 2 |
_aAntitubercular Agents _xtherapeutic use. |
|
| 650 | 2 |
_aTuberculosis _xdrug therapy. |
|
| 830 | 0 |
_aHenry Stewart talks. _pBiomedical & life sciences collection. _pTuberculosis. |
|
| 856 | 4 | 0 | _uhttps://hstalks.com/bs/2503/ |
| 856 | 4 | 2 |
_uhttps://hstalks.com/bs/p/686/ _3Series |
| 999 |
_c77236 _d77236 |
||